Curriculum Vitaes
Profile Information
- Affiliation
- Senoir Assistant Professor, Molecular Oncology, Fujita Health University
- Degree
- Ph.D. (Medical Science)(Apr, 2004, Nagoya University)
- Contact information
- slimsirichaikul
fujita-hu.ac.jp - J-GLOBAL ID
- 200901049510278132
- researchmap Member ID
- 1000314014
Research Areas
2Papers
20-
Cancers, 15(10) 2781-2781, May 16, 2023 Peer-reviewedInvitedLead authorCERS6 is associated with metastasis and poor prognosis in non-small cell lung cancer (NSCLC) patients through d18:1/C16:0 ceramide (C16 ceramide)-mediated cell migration, though the detailed mechanism has not been elucidated. In the present study, examinations including co-immunoprecipitation, liquid chromatography, and tandem mass spectrometry analysis were performed to identify a novel binding partner of CERS6. Among the examined candidates, LASP1 was a top-ranked binding partner, with the LIM domain possibly required for direct interaction. In accord with those findings, CERS6 and LASP1 were found to co-localize on lamellipodia in several lung cancer cell lines. Furthermore, silencing of CERS6 and/or LASP1 significantly suppressed cell migration and lamellipodia formation, whereas ectopic addition of C16 ceramide partially rescued those phenotypes. Both LASP1 and CERS6 showed co-immunoprecipitation with actin, with those interactions markedly reduced when the LASP1–CERS6 complex was abolished. Based on these findings, it is proposed that LASP1–CERS6 interaction promotes cancer cell migration.
-
Journal of Drug Delivery Science and Technology, 63 102443-102443, Jun, 2021 Peer-reviewed
-
Journal of Radiation Research, 60(1) 69-79, Jan 1, 2019 Peer-reviewed
-
Asian Journal of Pharmaceutical Sciences, 13(5) 425-437, Sep, 2018 Peer-reviewed
-
Oncotarget, 8(65) 109370-109381, Dec 12, 2017 Peer-reviewed
-
Genes, Chromosomes and Cancer, 55(8) 650-660, Aug, 2016 Peer-reviewed
-
Plant Molecular Biology, 88(6) 531-543, Aug, 2015 Peer-reviewed
-
Silpakorn Univ Sci Technol J., 9(1) 40-50, 2015 Peer-reviewedLead author
-
PLoS Genetics, 8(11) e1002945-e1002945, Nov 8, 2012 Peer-reviewed
-
Pharm Biol., 50(5) 578-579, 2012 Peer-reviewed
-
Thai J. Agric Sci., 44(5) 230-235, 2011 Peer-reviewed
-
Pharmaceutical Biology, 48(7) 740-744, Jul, 2010 Peer-reviewed
-
DNA Repair, 9(5) 534-541, May, 2010 Peer-reviewed
-
Molecular Cell, 37(5) 714-727, Mar, 2010 Peer-reviewed
-
The Journal of Biochemistry, 146(1) 13-21, Jul, 2009 Peer-reviewed
-
Nucleic Acids Research, 37(4) e31-e31, Dec 18, 2008 Peer-reviewedLead author
-
Bioscience, Biotechnology, and Biochemistry, 72(2) 630-635, Feb 23, 2008 Peer-reviewed
-
Molecular and Cellular Biology, 24(7) 2734-2746, Apr, 2004 Peer-reviewedABSTRACT We isolated active mutants in Saccharomyces cerevisiae DNA polymerase α that were associated with a defect in error discrimination. Among them, L868F DNA polymerase α has a spontaneous error frequency of 3 in 100 nucleotides and 570-fold lower replication fidelity than wild-type (WT) polymerase α. In vivo, mutant DNA polymerases confer a mutator phenotype and are synergistic with msh2 or msh6 , suggesting that DNA polymerase α-dependent replication errors are recognized and repaired by mismatch repair. In vitro, L868F DNA polymerase α catalyzes efficient bypass of a cis-syn cyclobutane pyrimidine dimer, extending the 3′ T 26,000-fold more efficiently than the WT. Phe34 is equivalent to residue Leu868 in translesion DNA polymerase η, and the F34L mutant of S. cerevisiae DNA polymerase η has reduced translesion DNA synthesis activity in vitro. These data suggest that high-fidelity DNA synthesis by DNA polymerase α is required for genomic stability in yeast. The data also suggest that the phenylalanine and leucine residues in translesion and replicative DNA polymerases, respectively, might have played a role in the functional evolution of these enzyme classes.
-
Planta Medica, 69(11) 1054-1056, Nov, 2003 Peer-reviewed
Misc.
1-
JOURNAL OF BIOCHEMISTRY, 148(2) 261-261, Aug, 2010
Presentations
6-
The 84th Annual Meeting of the Japanese Cancer Association, Sep 28, 2025
-
The 84th Annual Meeting of the Japanese Cancer Association, Sep 28, 2025
-
The 84th Annual Meeting of the Japanese Cancer Association, Sep 27, 2025
-
The 83rd Annual Meeting of the Japanese Cancer Association, 2024
-
The 81st Annual Meeting of the Japanese Cancer Association, Sep 30, 2022